FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I–III | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF +
Supplementary
Material

XML

Immunotherapy biomarkers

Original research

FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I–III

Online download statistics by month:

Online download statistics by month: May 2021 to March 2024

	Abstract	Full	Pdf
May 2021	417	417	179
Jun 2021	218	218	115
Jul 2021	178	178	76
Aug 2021	158	160	85
Sep 2021	108	108	33
Oct 2021	95	97	42
Nov 2021	89	88	49
Dec 2021	74	74	15
Jan 2022	54	56	31
Feb 2022	56	59	37
Mar 2022	88	93	46
Apr 2022	86	90	50
May 2022	74	76	39
Jun 2022	73	74	35
Jul 2022	49	49	36
Aug 2022	73	73	59
Sep 2022	77	79	74
Oct 2022	64	67	40
Nov 2022	55	57	29
Dec 2022	54	54	33
Jan 2023	57	57	29
Feb 2023	88	90	39
Mar 2023	74	75	60
Apr 2023	64	64	33
May 2023	81	82	39
Jun 2023	64	64	37
Jul 2023	56	56	40
Aug 2023	57	57	32
Sep 2023	73	73	37
Oct 2023	46	46	32
Nov 2023	49	50	35
Dec 2023	58	58	31
Jan 2024	39	40	33
Feb 2024	31	31	27
Mar 2024	42	42	26
Total	3019	3052	1633